IL10 and irritable bowel syndrome: High dose of JCM-16021 treatment significantly elevated the levels of TNF-α, IL-6, and IL-10, but not IFN-γ, in PI-IBS rats, suggesting that JCM-16021 may modulate mucosal cytokines production in PI-IBS rats.